Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.46 |
| ▸ | PDCD1LG2 | Q9BQ51 | 4/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29799944 | 1.00 | PNMT (0.46) | PNMTPDCD1LG2CD274TAAR1LOXL2 | |
| Hydrochloric Acid SCHEMBL18109266 | 0.98 | PNMT (0.45) | PNMTPDCD1LG2CD274TAAR1LOXL2 | |
| SCHEMBL31287302 | 0.84 | PNMT (0.48) | PNMTPDCD1LG2CD274TAAR1LOXL2 | |
| SCHEMBL22469536 | 0.84 | PNMT (0.48) | PNMTPDCD1LG2CD274TAAR1LOXL2 | |
| SCHEMBL1635301 | 0.82 | PNMT (0.46) | PNMTPDCD1LG2CD274TAAR1LOXL2 | |
| Hydrochloric Acid SCHEMBL2577836 | 0.82 | PNMT (0.46) | PNMTPDCD1LG2CD274TAAR1LOXL2 | |
| SCHEMBL30139647 | 0.82 | PNMT (0.58) | PNMTPDCD1LG2CD274TAAR1LOXL2 | |
| Hydrochloric Acid SCHEMBL1637469 | 0.80 | PNMT (0.45) | PNMTPDCD1LG2CD274TAAR1LOXL2 | |
| Hydrochloric Acid SCHEMBL2581982 | 0.80 | PNMT (0.45) | PNMTPDCD1LG2CD274TAAR1LOXL2 | |
| SCHEMBL210553 | 0.79 | PNMT (0.60) | PNMTTAAR1LOXL2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188089-A1 | SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-06-12 | — | — | US | disclosed |
| US-20250115619-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| US-20250115620-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| US-12227520-B2 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-12187734-B2 | Substituted pyridotriazine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-12122776-B2 | Tetracyclic compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| EP-4196479-B9 | SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4438123-A2 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20240300966-A1 | SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-09-12 | — | — | US | disclosed |
| US-12054496-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| WO-2014183532-A1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-11-20 | — | — | WO | disclosed |
| US-20140221356-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2014-08-07 | — | — | US | disclosed |
| US-20140221356-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2014-08-07 | — | — | US | disclosed |
| US-20140221356-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2014-08-07 | — | — | US | disclosed |
| WO-2014100323-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-8314250-B2 | Sultam derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-20 | — | — | US | disclosed |
| CN-102753538-A | Sultam derivatives | HOFFMANN LA ROCHE | 2012-10-24 | — | — | CN | disclosed |
| EP-2504324-A1 | SULTAM DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011064141-A1 | SULTAM DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-03 | — | — | WO | disclosed |
| US-20110124686-A1 | SULTAM DERIVATIVES | ANDERSON KEVIN W | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115619-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZYX, CCNY, NCAPD3 | PNMT 4378/4885PDCD1LG2 3661/4885CD274 2898/4885 |
| US-12122776-B2 | Tetracyclic compounds and uses thereof | HAVCR2, PAICS, CCR5 | PNMT 1078/4885PDCD1LG2 3562/4885CD274 2241/4885 |
| US-12227520-B2 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | ZYX, CCNY, XDH | PNMT 4242/4885PDCD1LG2 3844/4885CD274 3261/4885 |
| US-12054496-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | SDHA, SDHB, DHFR | PNMT 1995/4885PDCD1LG2 3240/4885CD274 2482/4885 |
| US-12187734-B2 | Substituted pyridotriazine compounds and uses thereof | TPMT, TYMP, DPYD | PNMT 168/4885PDCD1LG2 3222/4885CD274 2758/4885 |
| US-20250188089-A1 | SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF | TPMT, TYMP, DPYD | PNMT 168/4885PDCD1LG2 3222/4885CD274 2758/4885 |
| US-20140221356-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZC3HAV1, PYM1, ZC3HAV1L | PNMT 2392/4885PDCD1LG2 4102/4885CD274 2257/4885 |
| US-20250115620-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DHFR | PNMT 2169/4885PDCD1LG2 3319/4885CD274 2465/4885 |
| US-20110124686-A1 | SULTAM DERIVATIVES | SULT1A1, SULT2A1, SULT1E1 | PNMT 355/4885PDCD1LG2 4014/4885CD274 2586/4885 |
| US-20240300966-A1 | SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF | TPMT, TYMP, DPYD | PNMT 168/4885PDCD1LG2 3222/4885CD274 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.